PAX9 and breast cancer: In brief, the results indicate that the rs2236007 downregulates the gene expression of PAX9 by affecting the binding of suppressive transcription factor EGR1 and contributes to the malignancy of breast cancer with a poor prognosis for breast cancer patients.